Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).

Cameron RT, Coleman RG, Day JP, Yalla KC, Houslay MD, Adams DR, Shoichet BK, Baillie GS.

Biochem Pharmacol. 2013 May 1;85(9):1297-305. doi: 10.1016/j.bcp.2013.02.026. Epub 2013 Mar 5.


Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the β-agonist induced hypertrophic response in cardiac myocytes.

Sin YY, Edwards HV, Li X, Day JP, Christian F, Dunlop AJ, Adams DR, Zaccolo M, Houslay MD, Baillie GS.

J Mol Cell Cardiol. 2011 May;50(5):872-83. doi: 10.1016/j.yjmcc.2011.02.006. Epub 2011 Feb 18.


Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.

Song G, Zhao D, Hu D, Li Y, Jin H, Cui Z.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4610-4. doi: 10.1016/j.bmcl.2015.08.043. Epub 2015 Aug 21.


Pharmacophore modeling and virtual screening for the discovery of new type 4 cAMP phosphodiesterase (PDE4) inhibitors.

Niu M, Dong F, Tang S, Fida G, Qin J, Qiu J, Liu K, Gao W, Gu Y.

PLoS One. 2013 Dec 10;8(12):e82360. doi: 10.1371/journal.pone.0082360. eCollection 2013.


Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners.

Houslay KF, Christian F, MacLeod R, Adams DR, Houslay MD, Baillie GS.

Biochem J. 2017 Feb 15;474(4):597-609. doi: 10.1042/BCJ20160849. Epub 2016 Dec 19.


Phosphodiesterase 4 and its inhibitors in inflammatory diseases.

Jin SL, Ding SL, Lin SC.

Chang Gung Med J. 2012 May-Jun;35(3):197-210. Review.


Spatiotemporal dynamics of beta-adrenergic cAMP signals and L-type Ca2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases.

Leroy J, Abi-Gerges A, Nikolaev VO, Richter W, Lechêne P, Mazet JL, Conti M, Fischmeister R, Vandecasteele G.

Circ Res. 2008 May 9;102(9):1091-100. doi: 10.1161/CIRCRESAHA.107.167817. Epub 2008 Mar 27.


PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle.

Murthy KS, Zhou H, Makhlouf GM.

Am J Physiol Cell Physiol. 2002 Mar;282(3):C508-17.


New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment.

Brullo C, Ricciarelli R, Prickaerts J, Arancio O, Massa M, Rotolo C, Romussi A, Rebosio C, Marengo B, Pronzato MA, van Hagen BT, van Goethem NP, D'Ursi P, Orro A, Milanesi L, Guariento S, Cichero E, Fossa P, Fedele E, Bruno O.

Eur J Med Chem. 2016 Nov 29;124:82-102. doi: 10.1016/j.ejmech.2016.08.018. Epub 2016 Aug 13.


NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.

Yougbare I, Morin C, Senouvo FY, Sirois C, Albadine R, Lugnier C, Rousseau E.

Am J Physiol Lung Cell Mol Physiol. 2011 Oct;301(4):L441-50. doi: 10.1152/ajplung.00407.2010. Epub 2011 Jul 22.


Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains.

Bolger GB, Dunlop AJ, Meng D, Day JP, Klussmann E, Baillie GS, Adams DR, Houslay MD.

Cell Signal. 2015 Apr;27(4):756-69. doi: 10.1016/j.cellsig.2014.12.009. Epub 2014 Dec 27.


Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R.

Cell Signal. 2014 Sep;26(9):2016-29. doi: 10.1016/j.cellsig.2014.05.014. Epub 2014 May 29.


Mitotic activation of the DISC1-inducible cyclic AMP phosphodiesterase-4D9 (PDE4D9), through multi-site phosphorylation, influences cell cycle progression.

Sheppard CL, Lee LC, Hill EV, Henderson DJ, Anthony DF, Houslay DM, Yalla KC, Cairns LS, Dunlop AJ, Baillie GS, Huston E, Houslay MD.

Cell Signal. 2014 Sep;26(9):1958-74. doi: 10.1016/j.cellsig.2014.04.023. Epub 2014 May 9.


Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.

Avila DV, Barker DF, Zhang J, McClain CJ, Barve S, Gobejishvili L.

J Pathol. 2016 Sep;240(1):96-107. doi: 10.1002/path.4760.


β-Adrenergic cAMP signals are predominantly regulated by phosphodiesterase type 4 in cultured adult rat aortic smooth muscle cells.

Zhai K, Hubert F, Nicolas V, Ji G, Fischmeister R, Leblais V.

PLoS One. 2012;7(10):e47826. doi: 10.1371/journal.pone.0047826. Epub 2012 Oct 18.


Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Zhao CY, Greenstein JL, Winslow RL.

J Mol Cell Cardiol. 2015 Nov;88:29-38. doi: 10.1016/j.yjmcc.2015.09.011. Epub 2015 Sep 23.


Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.

Plummer MS, Cornicelli J, Roark H, Skalitzky DJ, Stankovic CJ, Bove S, Pandit J, Goodman A, Hicks J, Shahripour A, Beidler D, Lu XK, Sanchez B, Whitehead C, Sarver R, Braden T, Gowan R, Shen XQ, Welch K, Ogden A, Sadagopan N, Baum H, Miller H, Banotai C, Spessard C, Lightle S.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3438-42. doi: 10.1016/j.bmcl.2013.03.072. Epub 2013 Mar 28.


Supplemental Content

Support Center